Our approach to Crohn’s disease
Despite the ever-growing number of immunosuppressive drugs used for the treatment of Crohn’s disease, the course of disease progression has not changed for the majority of affected patients. Qu’s approach is not to suppress the symptoms of disease (which is the focus of current therapies) rather, Qu’s QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications. This would be transformative for those living with Crohn’s disease.
ABOUT OUR TRIAL
Qu Biologics is now recruiting Canadian residents to participate in the first stage of a new Phase 2 clinical trial of QBECO SSI for the treatment of adults living with moderate to severe Crohn’s disease.
The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. This study will also help determine whether mucosal healing occurs after 16 or 26 weeks of QBECO SSI treatment.
For more information, check out our webinars about the trial.
Thank you for your interest in participating in Qu Biologics’ Phase 2 clinical trial of an investigational new treatment for Crohn’s disease. To apply to participate, you will be asked to take a short questionnaire (16 questions) so that a recruitment nurse can assess your eligibility for this trial. The questionnaire and registration process will take about 10 minutes.
If at any time you have questions, you may speak with a Clinical Trial Representative at 1-877-223-8637 or firstname.lastname@example.org